Engineered immune cells take on Hard-to-Treat blood cancers
Disease control
Recruiting now
This study tests a treatment called JCAR017, made from a patient's own immune cells that are reprogrammed to attack cancer. It is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to other treatments. The st…
Phase: PHASE1, PHASE2 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated May 26, 2026 08:34 UTC